Relay Therapeutics
RLAY
161 hedge funds and large institutions have $1.64B invested in Relay Therapeutics in 2023 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 63 increasing their positions, 39 reducing their positions, and 24 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 39
40% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $1.02M
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
3% more funds holding
Funds holding: 157 → 161 (+4)
0.9% less ownership
Funds ownership: 107.95% → 107.05% (-0.9%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
24% less capital invested
Capital invested by funds: $2.16B → $1.64B (-$518M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$19.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.5M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$10.9M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$9.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$72.8M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$12.3M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.49M |
| 5 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$8.91M |
RLAY Hedge Fund Activity: Q2 2023 in Review
161 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2023, worth a combined $1.64B — down 24% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RLAY positions and 24 closed out — a net gain of 4 holders — while 63 added to existing stakes and 39 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $19.6M. The largest seller was Fidelity Investments, cutting an estimated $72.8M.
- 161 institutional investors held Relay Therapeutics (RLAY) as of Q2 2023, up from 157 in Q1 2023.
- Funds reported $1.64B of Relay Therapeutics stock for Q2 2023, down 24% quarter-over-quarter.
- 28 funds opened new Relay Therapeutics positions in Q2 2023 and 24 closed out, a net change of +4 holders.
- The largest Relay Therapeutics buyer in Q2 2023 was Millennium Management, an estimated $19.6M added.
- The largest Relay Therapeutics seller in Q2 2023 was Fidelity Investments, an estimated $72.8M sold.
Based on aggregated 13F filings for Q2 2023.